Cidara Therapeutics Statistics
Share Statistics
Cidara Therapeutics has 12.97M
shares outstanding. The number of shares has increased by 140.12%
in one year.
| Shares Outstanding | 12.97M |
| Shares Change (YoY) | 140.12% |
| Shares Change (QoQ) | 55.44% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,460 |
| FTD / Avg. Volume | 6.15% |
Short Selling Information
The latest short interest is 452.54K, so 3.61% of the outstanding
shares have been sold short.
| Short Interest | 452.54K |
| Short % of Shares Out | 3.61% |
| Short % of Float | 3.61% |
| Short Ratio (days to cover) | 4.83 |
Valuation Ratios
The PE ratio is -1.01 and the forward
PE ratio is -1.83.
Cidara Therapeutics's PEG ratio is
0.
| PE Ratio | -1.01 |
| Forward PE | -1.83 |
| PS Ratio | 133.87 |
| Forward PS | 1.7 |
| PB Ratio | 1.05 |
| P/FCF Ratio | -0.97 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cidara Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.25 |
| Quick Ratio | 4.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $33,552.63 |
| Profits Per Employee | $-4,469,131.58 |
| Employee Count | 38 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 53.46% in the
last 52 weeks. The beta is 0.86, so Cidara Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | 53.46% |
| 50-Day Moving Average | 20.8 |
| 200-Day Moving Average | 17.52 |
| Relative Strength Index (RSI) | 45.13 |
| Average Volume (20 Days) | 137,618 |
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of 1.27M
and earned -169.83M
in profits. Earnings per share was -26.75.
| Revenue | 1.27M |
| Gross Profit | -83.61M |
| Operating Income | -176.1M |
| Net Income | -169.83M |
| EBITDA | -176.1M |
| EBIT | -176.1M |
| Earnings Per Share (EPS) | -26.75 |
Full Income StatementBalance Sheet
The company has 189.82M in cash and 3.58M in
debt, giving a net cash position of 186.25M.
| Cash & Cash Equivalents | 189.82M |
| Total Debt | 3.58M |
| Net Cash | 186.25M |
| Retained Earnings | -611.26M |
| Total Assets | 214.8M |
| Working Capital | 161.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -176.53M
and capital expenditures -129K, giving a free cash flow of -176.66M.
| Operating Cash Flow | -176.53M |
| Capital Expenditures | -129K |
| Free Cash Flow | -176.66M |
| FCF Per Share | -27.82 |
Full Cash Flow StatementMargins
Gross margin is -6557.49%, with operating and profit margins of -13811.92% and -13319.76%.
| Gross Margin | -6557.49% |
| Operating Margin | -13811.92% |
| Pretax Margin | -13356.16% |
| Profit Margin | -13319.76% |
| EBITDA Margin | -13811.92% |
| EBIT Margin | -13811.92% |
| FCF Margin | -13855.84% |
